含富马酸伏诺拉生三联方案根除幽门螺杆菌的疗效观察
Observation on efficacy of triple therapy including vonoprazan in eradication of helicobacter pylori
汪海涛 1夏建新 1段和力1
作者信息
- 1. 063000 河北省唐山市,开滦总医院消化内科
- 折叠
摘要
目的 探讨富马酸伏诺拉生、阿莫西林、呋喃唑酮三联方案初次根除治疗幽门螺杆菌(Hp)的临床疗效及安全性.方法 选取2022年7月-2023年1月于开滦总医院消化内科门诊就诊216例患者进行前瞻性随机对照临床研究,均为13C-尿素呼气试验阳性且从未进行正规Hp根除治疗的慢性胃炎患者,随机分为A、B二组,A组(108例)给予10d含富马酸伏诺拉生三联方案(富马酸伏诺拉生+阿莫西林+呋喃唑酮);B组(108例)给予14d含艾普拉唑铋剂四联方案(艾普拉唑+胶体果胶铋+阿莫西林+呋喃唑酮).根除治疗结束后至少4周复查13C-尿素呼气试验,比较二组在Hp根除率及不良反应发生率方面的差异.结果 A组及B组根除率分别为93.3％和94.1％,差异无统计学意义(x2=0.046,P=0.830);二组不良反应发生率分别为5.7％和7.8％,差异无统计学意义(x2=0.371,P=0.542).结论 10d富马酸伏诺拉生、阿莫西林、呋喃唑酮三联方案与14d含艾普拉唑铋剂四联方案疗效相当,富马酸伏诺拉生方案具有疗程短、药物组成少的优势,是临床可供选择的安全、有效的初次根除方案.
Abstract
Objective To explore clinical efficacy and safety of vonoprazan,amoxicillin and furazolidone triple therapy in the first eradication of Helicobacter pylori treatment.Methods From July 2022 to January 2023,two hundred and sixteen patients were selected from the outpatient department of gastroenterology depart-ment of Kailuan General Hospital for a prospective randomized controlled clinical study,all of whom were positive for 13C-urea breath test and were not formal treated with Helicobacter pylori eradication.Randomly divided into group A and B.Group A(108 patients),10 days vonoprazan triple therapy(vonoprazan+amoxi-cillin+furazolidone).Group B(108 patients),14 days bismuth quadruple therapy containing ilaprazole(ila-prazole+colloidal bismuth pectin+amoxicillin+furazolidone).13C-urea breath test was reviewed at least four weeks after the end of eradication treatment,to compare the eradication rateand incidence of adverse reac-tions.Results The eradication rates in two groups were 93.3％and 94.1％,there was no statistically signifi-cant difference in eradication rates between two groups(x2=0.046,P=0.830).The incidence of adverse reac-tions in two groups was 5.7％and 7.8％,there was no statistically significant difference in the incidence of ad-verse reactions between two groups(x2=0.371,P=0.542).Conclusion The efficacy of 10-day vonoprazan triple therapy is equivalent to that of 14-day bismuth quadruple therapy containing ilaprazole.Vonoprazantriple therapy has the advantages of short course of treatment and less drug composition,which is a safe and effec-tive plan for the initial eradication of Helicobacter pylori that can be selected clinically.
关键词
幽门螺杆菌/富马酸伏诺拉生/根除率/铋剂四联疗法/三联方案Key words
Helicobacter pylori/Vonoprazan/Eradication rate/Bismuth quadruple therapy/Triple therapy引用本文复制引用
基金项目
河北省医学科学研究课题(2019)(20191329)
出版年
2024
NETL
NSTL
万方数据